Xie Qirun, the eldest granddaughter of Thailand's richest family, is sweet-looking, but she single-handedly controls the pharmaceutical overlord, a Chinese biopharmaceutical company, and is known as the "most beautiful CEO". According to data from the Hong Kong Stock Exchange on September 8, the total market value of China's biopharmaceuticals is currently 73.57 billion yuan.
The super "rich fourth generation" on the stage, at the helm of a 70 billion large enterprise, what will stir up the storm?
First, the sweet burden: 23 years old to run a 40 billion family business
Xie Qirun, born in 1992, is the fourth generation of the Xie family. Since grandpa's generation, the Xie family has been the leading family in Thailand, and has repeatedly topped the list of Thailand's richest people. In 2001, the idol drama "Meteor Garden" was popular in Southeast Asia, in which the home of The Dominion Temple was filmed in the 1.4 billion yuan worth of Tse Guomin's (Xie Qirun's fourth grandfather) - the Rich Golden House.
Although the Xie family is the richest man in Thailand, their ancestors are Chinese.
In 1922, Xie Yichu (Xie Qirun's grandfather) from a poor peasant family in Chaoshan, Guangdong Province, came to Bangkok alone with 8 silver dollars and founded the "Chia Tai Trang" rapeseed shop (the predecessor of the Chia Tai Group), nearly a hundred years later, the Chia Tai Group gradually formed a business territory with agriculture, pharmaceutical industry and food industry as the core, and grew into one of the world's largest Chinese multinational companies, with annual revenue accounting for 10% of Thailand's total GDP.
As the saying goes, "it is easy to open a store, it is difficult to keep a store", for a behemoth like Xie's, inheritance is already greater than making money. According to incomplete statistics, more than 80% of the world's family businesses ended in the hands of the second generation, and only 13% of them can survive normally until the third generation. Not long ago, Wang Sicong announced his withdrawal from the board of directors of Wanda Group, and Wang Jianlin, who had been busy for most of his life, fell into the embarrassment of no successor. In contrast, the fourth generation member Xie Qirun can control tens of billions of enterprises, which is particularly rare.
The Chaoshan people are good at business and are born with a burst of energy, although the Xie family has been lost overseas for nearly a hundred years. Xie Qirun, who carries the Chaoshan gene, still does not lack this toughness, coupled with talent and intelligence. Grandpa Xie Zhengming intends to cultivate him as a future heir, and every time he attends a commercial social occasion of the Thai royal family, he will take his granddaughter with him, and the seeds of business will sprout in Xie Qirun's heart.
In 2015, after graduating from the Wharton School of the University of Pennsylvania in the United States, Xie Qirun, who returned from his studies, did not forget his Chinese heart, applied to his family to join the Chinese nationality, and under the hand-pick of his grandfather Xie Zhengming, he joined the family's 40 billion market value of Chinese biopharmaceutical company and served as the chairman of the board.
Second, in the face of doubts, the "Princess of the Pharmaceutical World" became famous in the First World War
Xie Qirun, a 23-year-old chairman of the board of directors of a company with a market value of 40 billion yuan, was once questioned by the board of directors: "What can a little girl who doesn't understand anything have?" Just a vase! ”
At that time, Xie Qirun felt unprecedented external pressure, and she understood that only strength could block the mouths of the yo-yo crowd.
After joining the company, Xie Qirun did not show his official prestige, but regarded his subordinates as partners, conducted in-depth production front-line research, reorganized the management structure, and carried out organizational reform in a big way. In only half a year, he handed over a beautiful report card: revenue of HK$14.55 billion and net profit of HK$1.778 billion, an increase of 8.8% year-on-year, breaking the company's revenue and net profit records. Of course, for Xie Qirun, this is only a small step taken by the new official after taking office.
At the end of 2019, Xie Qirun made a "big move" again, announcing his stake in Kexing Zhongwei, which caused a strong backlash from the board of directors for a while, but he did not expect that only a few months later, the pandemic began to break out, the shortage of medical supplies, and the biomedical industry was also pushed to the cusp. Chinese biopharmaceutical companies invested $500 million to promote vaccine-related project research and development, resulting in a revenue of 26.8 billion. Xie Qirun became famous in the First World War and was known as the "Princess of the Medicine World".
According to the "Healthy China 2030" Planning Outline, the total value of the health service industry will exceed 8 trillion yuan in 2020 and is expected to peak 16 trillion yuan by 2030. The spring breeze of the medical and health industry has suddenly emerged, attracting capital to enter the market. Wanda Wang Jianlin has invested a large amount of 150 billion yuan to enter the big health, creating a new model of "multi-pronged" health industry that integrates medicine and medical treatment; Changshi Group Li Ka-shing and Huang Pharmaceutical, the first day of the hong Kong Stock Exchange bell- sounded the listing, the stock price soared 110%.
In the context of global aging, Nissan's "Pivero pro" life extension technology, which focuses on mitochondrial activation, has also emerged at this time. The intensive research of the R&D teams of the University of Tokyo and Kyoto University has made it land at Mitsukoshi Department Store in Ginza, Japan in 2019, which is favored by the local middle-aged and elderly groups. Two years later, "Paiweiluo pro" flowed into the mainland market through the Jingdong platform, even if the price threshold was speculated to four figures, there was no shortage of middle-class people in first-tier cities such as Beijing, Shanghai, Guangzhou, and Shenzhen to buy more than a dozen orders at a time.
According to the Fudan aging science popularization team "Time School", mitochondrials, as the energy supply station of human cells, are closely related to the physiological activities of cells, unfortunately, with the passage of age, there are different degrees of functional loss, which is aggravated after the age of 25. According to the human clinical confirmation of the Chinese Academy of Sciences, Guangti and other expert teams, the patented component of Mitelive in "Pivero pro" shows a positive trend in a number of physiological indicators such as aging reversal. Browsing the Jingdong page, there are many descriptions such as "energy enrichment" and "sleep optimization" in 6000+ feedback.
If Wang, Li and others are eyeing the huge dividends behind the biological health industry, then in contrast, Xie Qirun has more national enthusiasm. Faced with the situation that pharmaceutical companies in Western countries such as Lao Mei are dominant, Xie Qirun vowed to build China's biopharmaceutical companies into the top international pharmaceutical companies.
Third, the "most beautiful and rich four generations" are concerned about China, leading the company to "from imitation to creation"
In February 2020, Xie Qirun ranked 27th in The Forbes ' China's Outstanding Business Women Rankings" for 40 billion.
After naturalizing in China, her investment in the motherland did not decrease but increased.
At the end of 2021, in the face of repeated domestic pandemics, Xie Qirun donated 70,000 nucleic acid detection kits; In the first half of this year, the situation in Shanghai was not optimistic, and Chia Tai Group donated 1 million eggs free of charge to send charcoal in the snow.
In the context of domestic pharmaceutical companies in the context of innovation difficulties, Xie Qirun led China's biopharmaceuticals to the field of oncology, adding to the innovative drugs, the data shows that the company's research and development investment in innovative drugs in 2021 accounted for 70%, an increase of 64.7% year-on-year.
In the future, on the track of innovative drugs, what kind of answers Xie Qirun will hand over, it remains to be seen...